Lexeo Therapeutics (NASDAQ:LXEO) Given “Outperform” Rating at Leerink Partners

Lexeo Therapeutics (NASDAQ:LXEO)‘s stock had its “outperform” rating restated by Leerink Partners in a research report issued on Wednesday, September 23rd, Benzinga reports. They currently have a $15.00 price target on the stock. Leerink Partners’ price objective points to a potential upside of 325.89% from the stock’s current price.

Several other brokerages have also commented on LXEO. JPMorgan Chase & Co. decreased their price target on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, June 25th. Chardan Capital raised Lexeo Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Raymond James Financial reiterated a “strong-buy” rating on shares of Lexeo Therapeutics in a research report on Tuesday, September 22nd. Wall Street Zen upgraded Lexeo Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 19th. Finally, Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $18.13.

Lexeo Therapeutics Stock Up 3.0%

Shares of Lexeo Therapeutics stock traded up $0.10 during trading on Wednesday, reaching $3.52. The company’s stock had a trading volume of 180,663 shares, compared to its average volume of 981,165. The business has a 50 day moving average price of $4.50 and a 200-day moving average price of $5.05. Lexeo Therapeutics has a 12-month low of $2.98 and a 12-month high of $10.99. The company has a market capitalization of $288.97 million, a P/E ratio of -3.06 and a beta of 1.50.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.01). Research analysts predict that Lexeo Therapeutics will post -1.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Lexeo Therapeutics

Institutional investors have recently modified their holdings of the company. Legal & General Group Plc purchased a new position in Lexeo Therapeutics during the second quarter worth about $32,000. Allworth Financial LP grew its stake in shares of Lexeo Therapeutics by 1,002.9% during the 4th quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock valued at $34,000 after buying an additional 3,079 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Lexeo Therapeutics during the 4th quarter worth $37,000. Spark Investment Management LLC acquired a new stake in shares of Lexeo Therapeutics during the 2nd quarter worth $70,000. Finally, Canada Pension Plan Investment Board acquired a new position in Lexeo Therapeutics in the second quarter valued at $86,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for genetic and acquired diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material intended to address underlying disease mechanisms, with programs spanning central nervous system and cardiovascular conditions.

Lexeo’s development portfolio includes investigational therapies for APOE4-associated Alzheimer’s disease, Friedreich’s ataxia, and inherited cardiac disorders such as LMNA-related dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy.